Venture Capital

Updated:

Taiho Ventures

Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy...

Taiho Ventures logo

Taiho Ventures

Taiho Ventures, LLC is the corporate venture arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company focusing on oncology, allergy and immunology, and urology. With $400M under management, it actively invests in early stage private companies strategically relevant to Taiho Pharmaceutical. It considers company creation, spinouts and the option-type of investments as well as pure equity investments. Its mission is to create significant values from investing in the global biotech venture community and provide innovative science for Taiho Pharmaceutical Co., Ltd.

General information

Firm type

Venture Capital

Year founded

2017

Location

Region

Middle East

Country

United States

City

Menlo Park

Corporate office

Menlo Park, CA, United States

Additional offices

Abu Dhabi, United Arab Emirates · Princeton, NJ, United States · Chicago, IL, United States

Principals

Sakae Asanuma

Founder & Managing Partner

Sector focus

Digital HealthHealthcare ServicesAI/MLEnterprise Software

Frequently asked questions

Who leads investment decisions at Taiho Ventures?

Founder and Managing Partner Sakae Asanuma chairs the investment committee, drawing on his tenure as President of Astellas Pharma US. Day-to-day deal sourcing and diligence is conducted by a core team spread across the Menlo Park, Princeton, and Abu Dhabi offices, blending pharmaceutical operational experience with institutional venture backgrounds.

How is Taiho Ventures related to Taiho Pharmaceutical?

The firm operates independently but maintains a strategic relationship with Taiho Pharmaceutical, a Japanese oncology-focused pharma company that is one of its capital partners. Taiho Ventures is not a captive corporate venture arm; it manages capital from multiple sources, including family offices and sovereign-linked entities, allowing it to pursue investments beyond the parent pharma's immediate pipeline priorities.

Does Taiho participate in fund commitments or only direct deals?

Taiho Ventures is structured for direct early-stage equity investments and spin-off financings. There is no public record of the firm allocating to third-party venture funds as a limited partner, reinforcing its posture as a direct, thesis-driven investor rather than a fund-of-funds allocator.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Menlo Park Venture Capital profiles